|
Estimated Inhibition Constant, Ki (nmol), for ARBs docking into several immune system receptors. |
||||||
| Olmesartan |
Telmisartan |
Valsartan |
Irbesartan |
Candesartan |
Losartan |
|
|
|
||||||
| VDR,1DB1 |
12, 27 |
0.038 |
14 |
10 |
35 |
77 |
| VDR,1TXI |
10,34 |
0.039 |
14 |
12 |
30 |
74 |
| PPAR |
12 |
0.29 |
12 |
6 |
61 |
3 |
| CCR2b * |
9* |
25* |
22* |
9* |
39* |
25* |
| AT2R1 * |
0.10* |
0.10* |
0.3* |
0.17* |
1.5* |
0.50* |
|
*Note 1: CCR2b and AT2R1 are theoretical models, and may not be reliable (see text) Note 2: (conventional ligand binding data): 1,25-dihydroxyvitamin-D docks into VDR (PDB:1DB1) with Ki = 0.029 nmol and into VDR (PDB:1TXI) with Ki= 0.059 nmol TX522 docks into VDR (PDB:1DB1) with Ki = 0.071 nmol and VDR (PDB:1TXI) with Ki = 0.12 nmol TAK779 docks into putative CCR2b with Ki = 10 nmol GI262570 docks into PPAR (PDB:1FM9) with Ki = 0.040 nmol. | ||||||
Marshall et al. Theoretical Biology and Medical Modelling 2006 3:1 doi:10.1186/1742-4682-3-1 |
||||||